Actively Recruiting
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Led by National Cancer Institute (NCI) · Updated on 2026-05-08
285
Participants Needed
1
Research Sites
498 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible. White blood cells are then taken from the person s body, and the gene transfer occurs in a laboratory. A type of virus is used to transfer the genes that make those white blood cells able to attack the mutation in the tumor. The gene transfer therapy is the return of those white blood cells back to the person. Objective: To see if gene transfer therapy of white blood cells can shrink tumors. Eligibility: People with certain metastatic cancer for which standard treatments have not worked. Design: Participants may complete screening under another protocol. Screening includes: * Getting tumor cells from a previous procedure * Medical history * Physical exam * Scans * Blood, urine, heart, and lung tests The study has 8 stages: 1. Screening tests repeated over 1-2 weeks. Participants will have leukapheresis: Blood is removed by a needle in one arm. A machine removes white blood cells. The rest of the blood is returned by a needle in the other arm. 2. Care at home over approximately 12 weeks. 3. Stopping therapy for 4-6 weeks while their cells are changed in a lab. 4. Hospital stay approximately 3-4 weeks for treatment. An IV catheter will be placed in the chest to administer drugs. 5. Patients on Arm 2 of the study will receive the first dose of pembrolizumab while in the hospital. Three additional doses will be given after the cell infusion 3 weeks apart. 6. Receiving changed cells by catheter. Then getting a drug over 1-5 days to help the cells live longer. 7. Recover in the hospital for 1-2 weeks. Participants will get drugs and have blood and urine tests. 8. Participants will take an antibiotic and maybe an antiviral for at least 6 months after treatment. They will have repeat screening tests at visits every few months for the first year, every 6 months for the second year, then as determined.
CONDITIONS
Official Title
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 72 years
- Metastatic solid cancer measurable and in one of five cohorts: gastrointestinal/genitourinary; breast, ovarian, and other solid cancers; non-small cell lung cancer; endocrine/neuroendocrine tumors; multiple myeloma with measurable solid tumors
- Documented cancer diagnosis
- Cancer refractory to approved standard systemic therapies per cohort-specific treatments
- Three or fewer asymptomatic brain metastases less than 1 cm or stable treated brain lesions
- Clinical performance status of ECOG 0 or 1
- Willingness to use birth control during and after treatment if of child-bearing potential
- Negative pregnancy test if applicable
- Seronegative for HIV, hepatitis B antigen, and hepatitis C antibody (with additional testing if hepatitis C antibody positive)
- Adequate blood counts and organ function within specified limits
- Completed prior systemic therapy at enrollment
- Ability to understand and sign informed consent and durable power of attorney
- Co-enrollment on protocol 03-C-0277
You will not qualify if you...
- Pregnant or nursing
- Concurrent systemic steroid therapy
- Active systemic infections or major uncompensated medical illnesses
- Major bronchial occlusion or bleeding not treatable for non-small cell lung cancer cohort
- Primary immunodeficiency disorders
- History of major organ autoimmune disease
- For Arm 2: Grade 3 or 4 major organ immune-related adverse events from prior PD-1/PD-L1 treatment
- Opportunistic infections
- Severe hypersensitivity to cyclophosphamide, fludarabine, or aldesleukin
- Medical history compromising ability to tolerate high-dose aldesleukin (except low-dose allowed for some)
- History of coronary revascularization or ischemic symptoms
- Reduced heart function (LVEF ≤ 45%) or lung function (FEV1 ≤ 50%) if clinically indicated
- Use of other investigational agents
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Actively Recruiting
Research Team
N
NCI SB Immunotherapy Recruitment Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here